By a News Reporter-Staff News Editor at Health & Medicine Week -- New research on Hormones is the subject of a report. According to news reporting originating from Barcelona, Spain, by NewsRx correspondents, research stated, "Successful application clinical-grade human growth hormone (hGH) immunoassays to the discovery of illegal doping cases has been rare. Indeed, the preferred biological matrix in doping control is urine, where the estimated baseline concentration of hGH falls well below the linear range and sensitivity threshold of all commercially available immunoassays, including hGH isoform differential immunoassays which can discriminate pituitary endogenous hGH from recombinant hGH."
Our news editors obtained a quote from the research from the University of Pompeu Fabra, "We employed hydrogel nanoparticles as a pre-processing step that concentrate urinary hGH into the linear range of isoform differential immunoassays. We explored the characteristics of immunoassays in urine spiked with both phGH or rhGH, after pretreatment with the nanoparticles. Subsequently, pre-treatment was applied to urine obtained from 3 healthy volunteers administered during three days with daily subcutaneous injections of 0.026 mg/kg/day rhGH, Genotonorm ®. Linearity between both rhGH and phGH concentrations in urine measured by a chemoluminescent assay (Immulite) and in the particle eluate was evident for differential immunoassays (R square higher than 0.999). In case of treated individuals the recombinant/pituitary concentration ratios remained above the established World Anti-Doping Agency (WADA) criterion for hGH misuse up to 24 h after the last administration dose, using both assays for volunteer 1 and 2 while in case of volunteer 3 results were inconclusive."
According to the news editors, the research concluded: "The use of nanoparticles appears to open the possibility of assessing rhGH misuse in urine."
For more information on this research see: Analysis of urinary human growth hormone (hGH) using hydrogel nanoparticles and isoform differential immunoassays after short recombinant hGH treatment: Preliminary results. Journal of Pharmaceutical and Biomedical Analysis, 2013;85():194-197. Journal of Pharmaceutical and Biomedical Analysis can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Pharmaceutical and Biomedical Analysis - www.elsevier.com/wps/product/cws_home/525434)
The news editors report that additional information may be obtained by contacting J. Bosch, University of Pompeu Fabra, Dept. of Expt & Hlth Sci, Barcelona, Spain. Additional authors for this research include A. Luchini, S. Pichini, D. Tamburro, C. Fredolini, L. Liotta, E. Petricoin, R. Pacifici, F. Facchiano, J. Segura, E. Garaci and R. Gutierrez-Gallego (see also Hormones).
Keywords for this news article include: Spain, Europe, Alcohols, Hydrogel, Barcelona, Treatment, Nanoparticle, Nanotechnology, Growth Hormones, Peptide Hormones, Organic Chemicals, Polyethylene Glycols, Emerging Technologies, Anterior Pituitary Hormones
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC